Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.39 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 8/20 | 0.38 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | CBX7 | O95931 | 1/20 | 0.35 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.35 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2493765 | 0.89 | BRD4 (0.44) | AVPR2OXTRAVPR1AAVPR1BGPR65 | |
| SCHEMBL5065998 | 0.88 | ACHE (0.42) | AVPR2OXTRAVPR1AAVPR1BGPR65 | |
| SCHEMBL2499389 | 0.86 | AVPR1A (0.52) | AVPR2OXTRAVPR1AAVPR1BGPR65 | |
| SCHEMBL4479387 | 0.86 | AVPR1A (0.52) | AVPR2OXTRAVPR1AAVPR1BGPR65 | |
| SCHEMBL2500497 | 0.86 | AVPR1A (0.52) | AVPR2OXTRAVPR1AAVPR1BGPR65 | |
| SCHEMBL2499338 | 0.86 | AVPR1A (0.52) | AVPR2OXTRAVPR1AAVPR1BGPR65 | |
| SCHEMBL2495369 | 0.85 | AVPR2 (0.41) | AVPR2OXTRAVPR1AAVPR1BGPR65 | |
| SCHEMBL2498883 | 0.85 | ACHE (0.40) | AVPR2OXTRAVPR1AAVPR1BGPR65 | |
| SCHEMBL2495612 | 0.80 | BRD4 (0.54) | AVPR2OXTRAVPR1AAVPR1BGPR65 | |
| SCHEMBL5070494 | 0.79 | AVPR1A (0.51) | AVPR2OXTRAVPR1AAVPR1BGPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-7528124-B2 | 1,3-dihydro-2H-indol-2-one derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20060276449-A1 | 1,3-Dihydro-2h-indol-2-one derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1659121-A1 | 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276449-A1 | 1,3-Dihydro-2h-indol-2-one derivative | AVPR1B, AVPR2, AVPR1A | AVPR2 2/4885OXTR 26/4885AVPR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.